Overview

A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-02545920 In Psychiatrically Stable Subjects With Schizophrenia

Status:
Completed
Trial end date:
2013-10-17
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of multiple doses of PF 02545920 administered orally to psychiatrically stable subjects with schizophrenia receiving background antipsychotic +/- other adjunctive medication.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer